乳腺癌后更年期血管运动症状的植物性雌激素治疗
Marie Vogel1, Sebastian Franik1, Ludwig Kiesel1
1Department of Gynecology and Obstetrics, Münster University Hospital, Münster, Germany.
Breast care (Basel, Switzerland)
|August 2, 2023
概括
与安慰剂相比,植物性雌激素补充剂在乳腺癌患者中没有缓解更年期症状. 需要进一步的研究,为这些妇女找到安全有效的替代治疗方法.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 妇女健康 妇女健康
背景情况:
- 乳腺癌患者经常经历严重的绝经症状,影响生活质量.
- 激素替代疗法在乳腺癌幸存者中是禁忌的.
- 草本植物性雌激素制剂正在作为替代治疗方法进行探索.
研究的目的:
- 评估植物雌激素制剂在治疗乳腺癌患者更年期症状方面的疗效.
主要方法:
- 随机对照试验 (RCT) 的系统审查.
- 包括的研究比较了含有植物雌激素的产品与安慰剂.
- 分析的重点是症状的频率/严重程度,生活质量和不良事件.
主要成果:
- 与安慰剂相比,植物雌激素制剂没有显著的益处.
- 植物性雌激素并没有减少更年期症状的频率或严重程度.
- 与安慰剂相比,生活质量和不良事件没有得到改善.
结论:
- 目前的证据不支持在乳腺癌患者中使用植物性雌激素制剂治疗更年期症状.
- 需要进一步严格的RCT来确定安全有效的替代治疗方法.
- 建议制定一个核心成果集,以促进未来的研究综合.
相关概念视频
Menopause
202
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
202
Hormonal Regulation of the Menstrual Cycle
444
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
444
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
215
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
215
Disorders of the Female Reproductive System
409
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
409
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
201
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
201
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
316
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
316


